Russell Investments Group Ltd. Has $1.88 Million Position in Kiniksa Pharmaceuticals International, plc $KNSA

Key Points

• Russell Investments Group Ltd. significantly increased its holdings in Kiniksa Pharmaceuticals by 332,504% during the first quarter, now owning approximately 83,151 shares valued at $1.88 million.
• Wall Street analysts have shown confidence in Kiniksa Pharmaceuticals, with six analysts giving it a Buy rating and a consensus target price of $41.17.
• The company's stock experienced a modest increase of 1.6% and reported quarterly earnings with an EPS of $0.23, exceeding projected estimates.

Russell Investments Group Ltd. increased its stake in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) by 332,504.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 83,151 shares of the company's stock after purchasing an additional 83,126 shares during the quarter. Russell Investments Group Ltd. owned approximately 0.11% of Kiniksa Pharmaceuticals International worth $1,881,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. Wealth Enhancement Advisory Services LLC purchased a new position in Kiniksa Pharmaceuticals International in the first quarter valued at about $301,000. GAMMA Investing LLC increased its holdings in Kiniksa Pharmaceuticals International by 84.8% in the first quarter. GAMMA Investing LLC now owns 1,238 shares of the company's stock worth $27,000 after buying an additional 568 shares during the last quarter. Deutsche Bank AG increased its holdings in Kiniksa Pharmaceuticals International by 177.1% in the first quarter. Deutsche Bank AG now owns 394,522 shares of the company's stock worth $8,762,000 after buying an additional 252,125 shares during the last quarter. Victory Capital Management Inc. acquired a new position in Kiniksa Pharmaceuticals International in the first quarter worth approximately $1,184,000. Finally, Nuveen Asset Management LLC increased its holdings in Kiniksa Pharmaceuticals International by 7.3% in the fourth quarter. Nuveen Asset Management LLC now owns 795,612 shares of the company's stock worth $15,737,000 after buying an additional 54,361 shares during the last quarter. 53.95% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms recently commented on KNSA. Wells Fargo & Company increased their price objective on Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the stock an "overweight" rating in a report on Wednesday, July 9th. Jefferies Financial Group upped their target price on Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the stock a "buy" rating in a research report on Tuesday, July 29th. Wall Street Zen raised Kiniksa Pharmaceuticals International from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 2nd. Finally, Wedbush reaffirmed an "outperform" rating and set a $36.00 target price on shares of Kiniksa Pharmaceuticals International in a research report on Monday, July 21st. Six equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $41.17.

Insiders Place Their Bets

In related news, insider John F. Paolini sold 29,325 shares of the company's stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $32.55, for a total value of $954,528.75. Following the completion of the transaction, the insider directly owned 57,403 shares in the company, valued at approximately $1,868,467.65. This represents a 33.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Thomas Malley sold 78,233 shares of the stock in a transaction on Thursday, August 14th. The stock was sold at an average price of $33.09, for a total value of $2,588,729.97. Following the transaction, the director owned 12,546 shares of the company's stock, valued at $415,147.14. This represents a 86.18% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 593,416 shares of company stock valued at $18,924,806 in the last ninety days. 53.48% of the stock is currently owned by insiders.

Kiniksa Pharmaceuticals International Stock Down 0.0%

Shares of KNSA stock traded down $0.01 during trading hours on Friday, reaching $33.49. 316,932 shares of the company's stock were exchanged, compared to its average volume of 555,267. Kiniksa Pharmaceuticals International, plc has a fifty-two week low of $17.82 and a fifty-two week high of $34.55. The stock has a market capitalization of $2.48 billion, a P/E ratio of 837.46 and a beta of 0.14. The business has a fifty day moving average price of $30.31 and a 200-day moving average price of $25.97.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last issued its quarterly earnings results on Tuesday, July 29th. The company reported $0.23 EPS for the quarter, topping analysts' consensus estimates of $0.18 by $0.05. The company had revenue of $156.80 million during the quarter, compared to analyst estimates of $145.21 million. Kiniksa Pharmaceuticals International had a return on equity of 1.05% and a net margin of 0.90%. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. As a group, research analysts expect that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current fiscal year.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.